Assessing the Impact of Time to Cystectomy for Variant Histology of Urothelial Bladder Cancer.

To determine if the timing of radical cystectomy for variant histology of urothelial carcinoma has an impact on survival. Variant histology has been associated with aberrant behavior compared to pure urothelial carcinoma, however the timing of surgery for these patients has not been studied.

We identified 363 patients with cT2-T4N0M0 urothelial carcinoma who underwent radical cystectomy without perioperative intravesical and/or systemic therapy from 2003 to 2014. Clinicopathologic data was compared between pure urothelial carcinoma and variant histology. The time from diagnosis to radical cystectomy was analyzed as a continuous variable and dichotomized at 4-, 8-, and 12-weeks to determine impact on oncologic outcomes.

Patients with variant histology, when compared to those with pure urothelial carcinoma, were more likely to present with extravesical disease (p<0.01), be upstaged (p<0.01), have lymphovascular invasion (p<0.01) and have lymph node metastasis at radical cystectomy (p=0.02). The median days to radical cystectomy did not differ between pure urothelial and variant histology. On multivariable analysis controlling for age, comorbidities, tumor stage, lymph node status, lymphovascular invasion, and surgical margins, every month in delay was associated with a worse overall survival for variants (HR=1.36, p=0.003). At an 8-week delay or longer, those with variant histology had a statistically worse survival (p=0.03).

For patients with variant histology, delays in surgery were associated with an increased risk of death.

Urology. 2019 Aug 14 [Epub ahead of print]

Michael Lin-Brande, Shane M Pearce, Akbar N Ashrafi, Azadeh Nazemi, Madeleine L Burg, Saum Ghodoussipour, Gus Miranda, Hooman Djaladat, Anne Schuckman, Siamak Daneshmand

USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: ., USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: ., USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: ., USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: ., USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: ., USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: ., USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: ., USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: ., USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: ., USC Institute of Urology, USC/Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA. Electronic address: .

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe